Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 35% · prior close shown (market closed)
Limited proprietary earnings coverage for MLYS yet — signals will sharpen as filings and earnings are ingested.
Pipeline evidence · 16d ago
MLYS's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on MLYS.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Mineralys Therapeutics, Inc. (MLYS) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
AlphaOS industries
Investment snapshot
MLYS's AI investment thesis
Upgrade to Premium for MLYS's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$26.59
Market cap
$2.35B
Profitable
—
Net income
—
FY Sep 5, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Mineralys Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Mineralys Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.